Search

Your search keyword '"Montanari, E."' showing total 99 results
Start Over Author "Montanari, E." Language undetermined
99 results on '"Montanari, E."'

1. Urologists are optimistic surgeons: prevalence and predictors of discordance between intraoperative stone-free rate and cross-sectional imaging evaluation after vacuum-assisted mini-percutaneous nephrolithotomy

Author

Jannello LMI, Turetti M, Silvani C, Galbiati G, Garbagnati S, Pozzi E, Malfatto M, Zanetti SP, Longo F, De Lorenzis E, Albo G, Salonia A, Montanari E, Boeri L, Jannello, Lmi, Turetti, M, Silvani, C, Galbiati, G, Garbagnati, S, Pozzi, E, Malfatto, M, Zanetti, Sp, Longo, F, De Lorenzis, E, Albo, G, Salonia, A, Montanari, E, and Boeri, L

Published
2022

2. The Effect of CO2 Pressure and Flow Variation on Carbon Particles Spread During Pneumoperitoneum: An Experimental Study

Author

Gallioli, A, De Lorenzis, E, Lievore, E, Boeri, L, Colombo, L, Fontana, M, Breda, A, Montanari, E, and Albo, G

Subjects
robotics, surgical oncology, urothelial cancer, laparoscopy, pneumoperitoneum
Abstract

Background: A correlation between atypical recurrences and minimally-invasive surgery has been suggested in case of urothelial cancer; however, few data are available on the role of pneumoperitoneum in terms of gas flow and intra-abdominal pressure. The objective of the study is to analyze the impact of CO2 pneumoperitoneum variation on an inert material as surrogate of neoplastic cells. Material and Methods: We designed an experimental model mimicking pneumoperitoneum in three settings: sealed flow (no leakage), pulsatile flow (alternating efflux and influx), and continuous flow (AirSeal degrees insufflator). Each experiment was characterized by a predetermined gas flow and pressure, trocar distance, and position from the particles. Hounsfield density (HD) variation in the areas of interest was measured as index of graphite powder dispersion. A Linear Regression Model was used to measure the correlation between modifiable variables and HD. Results: HD was lower in the pulsatile compared to both the sealed and continuous flows (p 0.05). Conclusions: Flow and pressure setting, inflow trocar distance and contiguity from the tumor, and pneumoperitoneum stability may be all crucial components in minimally invasive surgery. In vivo, these variables should be considered as potential risk factors for tumor cells spread within the abdominal cavity.

Published
2022

3. Suitability of miRNA assessment in postmortem interval estimation

Author

Montanari, E, Giorgetti, R, Busardò, F P, Giorgetti, A, Tagliabracci, A, Alessandrini, F, Montanari, E, Giorgetti, R, Busardò, F P, Giorgetti, A, Tagliabracci, A, and Alessandrini, F

Subjects
MicroRNAs, Postmortem Changes, Forensic, Humans, MicroRNA, Forensic Pathology, Polymerase Chain Reaction, Post-mortem interval (PMI), Human
Abstract

OBJECTIVE: The aim of this review was to explore recent pieces of evidence focused on the use of miRNAs for PMI estimation both in humans and animal experiments, with particular interest on the best miRNAs to use as reference/target markers in different tissues or biological fluids. MiRNAs are innovative biomarkers used in clinical and research field: they appear very attractive, being introduced in forensic research scenarios even for PMI estimation.MATERIALS AND METHODS: Data from PubMed and Scopus were analyzed from January 2013 to August 2020. Based on inclusion/exclusion criteria, high-quality articles have been selected to become the subject of this review.RESULTS: A total of 737 papers were found but, after titles/abstracts screening for inclusion criteria and a full-text careful selection, 33 papers were deeply studied. After the exclusion of 19 papers, 15 articles remained. Eight papers dealt with animals (mice/rats), two both with animals and humans (for method validation previously built), while 5 exclusively with humans. Myocardium (6/15) and brain (6/15) were the most studied tissues. respectively in mice/rats and humans. PMI considered was up to 7.5 days in mouse studies and less than 3 days in human models.CONCLUSIONS: Because of their significant stability in both early and long PMI, miRNAs are the cleverest reference markers to be used. Temperature and environmental conditions influence mostly mRNA, while miRNAs are less susceptible to them. The best miRNA to choose depends on its tissue specificity, i.e., miR-9 and miR-125 in brain or miR-1 and miR-133 in skeletal muscle/heart.

Published
2021

4. Predictors of residual tumor at re-staging transurethral resection for high-risk non-muscle invasive bladder cancer: Insights from a large multi-institutional collaboration

Author

Claps, F., Pavan, N., Nicola d'Altilia, Checcucci, E., Napolitano, L., Morlacco, A., Tafuri, A., Palumbo, C., Boeri, L., Tulone, G., Bignu, C., Liguori, G., Busetto, G. M., Simonato, A., Montanari, E., Carmignani, L., Celia, A., Volpe, A., Antonelli, A., Dal Moro, F., Mirone, V., Porpiglia, F., Cormio, L., Carrieri, G., and Trombetta, C.

Subjects
Urology
Published
2022

5. Diagnosis of prostate cancer in men treated with 5-alpha-reducates inhibitors with multi-parametric MRI: Results of a multicenter international collaboration

Author

ugo falagario, Lantz, A., Jambor, I., Busetto, G. M., Carmignani, L., Montanari, E., Bove, P., Gontero, P., Sciarra, A., Di Tonno, P., Trombetta, C., Bassi, P., Simone, G., Mirone, V., Antonelli, A., Schips, L., Bostrom, P., Porpiglia, F., T, Nordstrom, Cobelli, O., Cormio, L., Carrieri, G., and Ferro, M.

Subjects
Urology
Published
2022

6. A consecutive series of patients undergoing trans-urethral cystolithotripsy with ballistic lithotripsy by a tertiary referral center for neurogenic bladder

Author

Maltagliati, M., Sampogna, G., Citeri, M., Stefaniaguerrer, C., Zanollo, L. G., Rizzato, L., Montanari, E., Micali, S., Rocco, B., and Spinelli, M.

Subjects
Male, Urinary Bladder Calculi, Trans-urethral cystolithotripsy, Neurogenic bladder, neurogenic bladder, Ballistic lithotripsy, Bladder stone, Spinal cord injury, spinal cord injury, bladder stone, Tertiary Care Centers, Treatment Outcome, Lithotripsy, Humans, Original Article, Urinary Bladder, Neurogenic, ballistic lithotripsy, trans-urethral cystolithotripsy, Retrospective Studies
Abstract

Background and aim of the work: Patients with neurogenic bladder (NB) have an increased risk of developing bladder stones due to bladder catheter, incomplete bladder emptying, recurrent urinary tract infections, and immobilization. In these patients, minimally invasive treatments are usually adopted, as noninvasive extracorporeal shockwave lithotripsy is limited by the risk of not clearing all stone fragments, and open surgery is usually discouraged. The aim of our study was to present our experience with trans-urethral cystolithotripsy (TUCL) in patients treated by a tertiary referral center for NB. Methods: We retrospectively collected pre-, intra- and post-operative data from our patients, who underwent TUCL from October 2013 to October 2019. The procedure was performed with a 24 Fr cystoscope and a ballistic lithotripter. Lapaxy was performed with Ellik bladder evacuator. All procedures were performed by two expert surgeons. Stone-free rate (SFR) was defined as the percentage of patients with absence of residual fragments >2 mm in diameter. Results: We performed consecutively 91 TUCLs in 75 patients during the selected period. SFR was 94.1%. Intra- and post-operative complications occurred in one (1.1%) patient. Our statistical analysis outlined the SFR was affected in a statistically significant way by sex, NB etiology, stone cumulative diameter, and operative time. Conclusion: Our series proved the safety and efficacy of TUCL with ballistic lithotripsy in NB patients. Further multicenter randomized controlled trials are mandatory to validate definitively TUCL as the gold standard therapy for bladder urolithiasis in NB patients, and to identify risk factors limiting the SFR. (www.actabiomedica.it)

Published
2019

7. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study

Author

Fasano, Antonio, Fini, Nicola, Ferraro, Diana, Ferri, Laura, Vinceti, Marco, Mandrioli, Jessica, Mandrioli, J., Fini, N., Fasano, A., Nichelli, P., Biguzzi, S., Handouk, Y., Venturini, E., Passarin, M. G., Guidi, C., Neri, W., Sette, E., Tugnoli, V., Tola, M. R., Terlizzi, E., Guidetti, D., Currò Dossi, M., Pasquinelli, M., Andruccioli, J., Ravasio, A., Casmiro, M., Rasi, F., Salvi, F., Bartolomei, I., Michelucci, R., Avoni, P., De Pasqua, S., Liguori, R., Rizzi, R., Canali, E., Marcello, N., Taga, A., Zinno, L., Pietrini, V., Aiello, M., Medici, D., Chierici, E., Montanari, E., Santangelo, M., Amidei, S., Casetta, Ilaria, Groppo, E., Granieri, Enrico Gavino Giuseppe, De Massis, P., Mussuto, V., Borghi, A., Gabellini, A., Sacquegna, T., Rinaldi, R., Cirignotta, F., Ferro, S., and D'Alessandro, R.

Subjects
Male, medicine.medical_specialty, Neurology, medicine.medical_treatment, Population, Amyotrophic lateral sclerosis, body weight loss, percutaneous endoscopic gastrostomy, population-based study, survival, Neurology (clinical), macromolecular substances, Enteral administration, Endoscopy, Gastrointestinal, Amyotrophic lateral sclerosis, percutaneous endoscopic gastrostomy, body weight loss, survival, population-based study, Body Mass Index, NO, Cohort Studies, 03 medical and health sciences, Enteral Nutrition, Tracheostomy, 0302 clinical medicine, Percutaneous endoscopic gastrostomy, Weight Loss, PEG ratio, medicine, Humans, Registries, 030212 general & internal medicine, education, Aged, Gastrostomy, education.field_of_study, business.industry, Middle Aged, medicine.disease, Survival Analysis, Surgery, Treatment Outcome, Italy, Cohort, Female, Observational study, Deglutition Disorders, business, 030217 neurology & neurosurgery
Abstract

To assess the role of percutaneous endoscopic gastrostomy (PEG) insertion, and its timing, on ALS survival, and to study prognostic factors of survival before and after PEG placement in a population-based setting.In this observational population-based, registry study, we enrolled patients with newly- diagnosed ALS, according to the El Escorial revised criteria, who were resident in the Emilia Romagna Region, and who developed severe dysphagia needing enteral nutritional support. The primary outcome measure was tracheostomy-free survival after PEG recommendation.There were 210 patients needing PEG, out of an incident cohort of 545 patients from the Emilia Romagna Registry for ALS, who were diagnosed between 2009 and 2013. One hundred and ninety-three patients were included in the study, and 17 were excluded because they were already tracheostomized at the time of PEG placement. Of the 193 patients included in the study, 152 underwent PEG, whereas 41 did not undergo the procedure. Patients who did not undergo PEG, among the eligible ones, had the same tracheostomy-free survival from onset as patients who did (25 vs. 32 months, p = 0.21). Tracheostomy-free survival from PEG recommendation was greater in patients who underwent PEG placement than in patients who did not (6 vs. 2 months, p = 0.008). Median tracheostomy-free survival from PEG insertion was eight months (95% CI5-12); 30 days after PEG placement, survival was 89.60%. At Cox multivariable analysis, the hazard of death or tracheostomy after PEG insertion was significantly influenced by the difference between BMI at the time of the PEG procedure and BMI at diagnosis (HR 1.05, 95% CI 1.02-1.08; p = 0.002). The hazard of death or tracheostomy was not affected by the timing of PEG insertion.The present study, although it has some limitations, suggests a gain of tracheostomy-free survival from the time of PEG recommendation for patients who undergo PEG placement, and, among patients who undergo PEG, a greater survival if PEG is inserted before a significant weight loss occurs, and if nutritional support avoids further weight loss. Should this association between prevention of weight loss and better clinical outcome be confirmed by further studies, it would have important implications for disease management.

Published
2017

8. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements

Author

Franchignoni, Franco, Mandrioli, Jessica, Giordano, Andrea, Ferro, Salvatore, Mandrioli, J., Fini, N., Georgoulopoulou, E., Nichelli, P., Biguzzi, S., Venturini, E., Passarin, M. G., Guidi, C., Neri, W., Sette, E., Tugnoli, V., Tola, M. R., Terlizzi, E., Guidetti, D., Curro Dossi, M., Pasquinelli, M., Andruccioli, J., Ravasio, A., Casmiro, M., Rasi, F., Salvi, F., Bartolomei, I., Michelucci, R., Avoni, P., De Pasqua, S., Liguori, R., Rizzi, R., Canali, E., Marcello, N., Grassi, A., Delay, L., Pietrini, V., Aiello, M., Chierici, E., Montanari, E., Santangelo, M., Amidei, S., Greco, G., Casetta, I., Groppo, E., Granieri, E., De Massis, P., Mussuto, V., Borghi, A., Gabellini, A., Sacquegna, T., Rinaldi, R., Cirignotta, F., Ferro, S., D'Alessandro, R., Franchignoni, Franco, Mandrioli, Jessica, Giordano, Andrea, Ferro, Salvatore, Mandrioli, J., Fini, N., Georgoulopoulou, E., Nichelli, P., Biguzzi, S., Venturini, E., Passarin, M.G., Guidi, C., Neri, W., Sette, E., Tugnoli, V., Tola, M.R., Terlizzi, E., Guidetti, D., Curro Dossi, M., Pasquinelli, M., Andruccioli, J., Ravasio, A., Casmiro, M., Rasi, F., Salvi, F., Bartolomei, I., Michelucci, R., Avoni, P., De Pasqua, S., Liguori, R., Rizzi, R., Canali, E., Marcello, N., Grassi, A., Delay, L., Pietrini, V., Aiello, M., Chierici, E., Montanari, E., Santangelo, M., Amidei, S., Greco, G., Casetta, I., Groppo, E., Granieri, E., De Massis, P., Mussuto, V., Borghi, A., Gabellini, A., Sacquegna, T., Rinaldi, R., Cirignotta, F., Ferro, S., and D'Alessandro, R.

Subjects
Rasch analysi, Adult, Male, medicine.medical_specialty, Psychometrics, Community Health Planning, Retrospective Studie, ALSFRS-R, medicine, Humans, Respiratory function, Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosi, population based study, Aged, Retrospective Studies, Rasch model, Alsfrs r, Amyotrophic Lateral Sclerosis, Rasch analysis, Retrospective cohort study, Middle Aged, medicine.disease, Differential item functioning, Confirmatory factor analysis, Neurology, Physical therapy, Female, Neurology (clinical), Factor Analysis, Statistical, Psychology, Psychometric, Human
Abstract

Our objective was to verify and expand previous evidence of psychometric inadequacies in the ALSFRS-R, in a different sample of subjects suffering from ALS. Since 2009, a prospective registry records all incident cases of ALS in Emilia Romagna Region, Italy (4.4 million inhabitants) referred to its 17 neurological departments. For each patient, demographic and clinical information is collected by the physician in charge, including compilation of the ALSFRS-R at each clinical follow-up. Results showed that a confirmatory factor analysis on the three-factor model previously found (bulbar, motor, respiratory function) showed a good fit. Rasch analysis on the whole scale showed the need to collapse some rating categories, confirmed the multidimensionality of the ALSFRS-R, and demonstrated the presence of differential item functioning between patients with spinal versus bulbar onset. Moreover, some items included in the three ALSFRS-R subscales showed a problematic fit to the respective construct they were intended to measure. In conclusion, the interpretation of a total raw score of ALSFRS-R is hampered by ambiguities due to the different metric properties of the three domains the scale aggregates, and their content and structure. This study confirms that a refinement of ALSFRS-R is warranted, pointing to the need to revise its whole structure, and providing detailed guidelines for its revision.

Published
2015

9. Comparison of Flexible Ureterorenoscope Quality of Vision: An In Vitro Study

Author

Talso, M, Proietti, S, Emiliani, E, Gallioli, A, Dragos, L, Orosa, A, Servian, P, Barreiro, A, Giusti, G, Montanari, E, Somani, B, Traxer, O, and PETRA Grp

Subjects
vision, flexible ureterorenoscope, quality of vision, digital ureterorenoscope, endourology, image definition
Abstract

Introduction: Flexible ureterorenoscopy (fURS) is one of the best solutions for treatment of renal calculi

Published
2018

10. Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study

Author

Patti, F., Lo Fermo, S., Maimone, D., Messina, S., D'Amico, E., Cimino, V., Gasperini, C., Galgani, S., Orefice, V., Brescia Morra, V., Florio, C., Amato, M., Goretti, B., Portaccio, E., Zipoli, V., Bertolotto, A., Bramanti, P., Sessa, E., Centonze, D., Cottone, S., Salemi, G., Falcini, M., Gallo, P., Perini, P., Gigli, G., Giuliani, G., Pucci, S., Grimaldi, L., Murri, L., Lugaresi, A., Monaco, F., Montanari, E., Motti, L., Neri, S., Paciello, M., Provinciali, L., Ragno, M., Rosati, G., Ruggieri, S., Bell'Antonio, P., Tola, M., Caniatti, L., Tonali, P., Batocchi, A., Trojano, M., Di Monte, E., De Caro, M., Ghezzi, A., Zaffaroni, M., Zolo, P., Zorzon, M., Signorino, M., Scarpini, E., Durelli, L., Carolei, A., Todaro, M., Todaro, R., Spitaleri, D., Tartaglione, A., Patti, F, Amato, Mp, Trojano, M, Bastianello, S, Tola, Mr, Picconi, O, Cilia, S, Cottone, S, Centonze, D, Gasperini, C, BRESCIA MORRA, Vincenzo, Lo Fermo, S, Maimone, D, Messina, S, D'Amico, E, Cimino, V, Galgani, S, Orefice, V, Brescia Morra, V, Florio, C, Amato, MP, Goretti, B, Portaccio, E, Zipoli, V, Bertolotto, A, Bramanti, P, Sessa, E, Salemi, G, Falcini, M, Gallo, P, Perini, P, Gigli, GL, Giuliani, G, Pucci, S, Grimaldi, LM, Murri, L, Lugaresi, A, Monaco, F, Montanari, E, Motti, L, Neri, S, Paciello, M, Provinciali, L, Ragno, M, Rosati, G, Ruggieri, S, Bell'antonio, P, Tola, MR, Caniatti, L, Tonali, P, Batocchi, AP, Di Monte, E, De Caro, MF, Ghezzi, A, Zaffaroni, M, Zolo, P, Zorzon, M, Signorino, M, Scarpini, E, Durelli, L, Carolei, A, Todaro, M, Todaro, R, Spitaleri, D, Tartaglione, A, Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C, COGIMUS Study Group, and Lugaresi A

Subjects
Adult, Male, Quality of life, Longitudinal study, medicine.medical_specialty, Injections, Subcutaneous, multiple sclerosis, Relapsing-Remitting Multiple Sclerosis, Interferon beta 1a, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Adjuvants, Immunologic, Internal medicine, medicine, Humans, Young adult, Fatigue, Depression (differential diagnoses), Aged, Depression, business.industry, Cognitive function, Multiple sclerosis, Cognitive disorder, Interferon beta-1a, Interferon-beta, Middle Aged, medicine.disease, Clinical trial, Neurology, Physical therapy, multiple sclerosis, cognition, interferon beta, Female, Settore MED/26 - Neurologia, Neurology (clinical), Cognition Disorders, business, medicine.drug
Abstract

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, and 163 received interferon beta-1a, 22 µg subcutaneously three times weekly). Mean MS Quality of Life-54 (MSQoL-54) composite scores did not change over time. There were no significant differences between groups in MSQoL-54 composite scores when patients were grouped by treatment dose and baseline cognitive status. Mean (standard deviation) Hamilton Depression Rating Scale score decreased from 6.8 (4.9) at baseline to 5.8 (5.9) at year 3. Mean total Fatigue Impact Scale scores were low ( Conclusion: Quality of life, depression and fatigue remained largely stable over 3 years; no effects of treatment dose or baseline cognitive status were found.

Published
2011

11. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

Author

Paul, O'Connor, Wolinsky, Jerry S., Christian, Confavreux, Giancarlo, Comi, Ludwig, Kappos, Olsson, Tomas P., Hadj, Benzerdjeb, Philippe, Truffinet, Lin, Wang, Aaron, Miller, Temso Trial Group Reingold, Freedman Ms S., Cutter, G., Antel, J., Barkhof, F., Maddrey, W., Ravnborg, M., Schenker, S., O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Miller, A., Freedman, Mark S., Narayana, P. A., Nelson, F., Vainrub, I., Datta, S., He, R., Gates, B., Ton, K., Wamil, B., Truffinet, P., Igau, B., Nicolas, V., Notelet, L., Payrard, S., Wijnand, P., Devore, S., H. H., Li, Osho, T., Wang, L., Wei, L., Dukovic, D., Ling, Y., Benzerdjeb, H., Mednikova, Z., Trabelsi, N., Musset, M., Merrill, D., Turpault, S., Williams, B., Nortmeyer, H., Kirst, E., Witthaus, E., Chen, S., Maida, E., Auff, E., Fazekas, F., Berger, T., Bhan, V., Bouchard, J. P., Duquette, P., Freedman, M., Grand'Maison, F., Kremenchutzky, M., Bourque, C., Marrie, R. A., Melanson, M., Patry, D., Oger, J., Stefanelli, M., Jacques, F., Venegas, P., Miranda, M., Barrientos, N., Tenhamm, E., Gloger, S., Rohde, G., Mares, J., Frederiksen, J., Stenager, E., Haldre, S., Gross Paju, K., Elovaara, I., Sumelahti, M. L., Erälinna, J. P., Farkkila, M., Harno, H., Reunanen, M., Jolma, T., Camu, W., Clavelou, P., Magy, L., Debouverie, M., Edan, G., Lebrun Frenay, C., Moreau, T., Pelletier, J., Roullet, E., Alamowitch, S., Clanet, M., Hautecoeur, P., Damier, P., Rumbach, L., Chan, A., Schimrigk, S., Haas, J., Lensch, E., Diener, H., Limmroth, V., Anders, D., Berghoff, M., Oschmann, P., Stangel, M., Frese, A., Kiefer, R., Marziniak, M., Zettl, U., Stark, E., Jendroska, K., Reifschneider, G., Amato, M. P., Cosi, V., Gallo, P., Gasperini, Claudio, Ghezzi, A., Trojano, M., Pozzilli, Carlo, Montanari, E., Zwanikken, C. P., Jongen, P. J., Van Munster, E. T., Hupperts, R. M., Anten, B., Sanders, E. A., Celius, E., Hovdal, H., Krogseth, S. B., Kozubski, W., Kwiecinski, H., Czlonkowska, A., Stelmasiak, Z., Selmaj, K., Hasiec, T., Fryze, W., Drozdowski, W., Kochanowicz, J., Cunha, L., De Sa, J., Sena, A. H., Odinak, M., Skoromets, A., Gusev, E., Boiko, A., Lashch, N., Stolyarov, I., Belova, A., Malkova, N., Doronin, B., Yakupov, E., Brundin, L., Hillert, J., Karabudak, R., Irkec, C., Idiman, E., Turan, O., Efendi, H., Gedizlioglu, M., Buchakchyyska, N., Goloborodko, A., Ipatov, A., Kobets, S., Lebedynets, V., Moskovko, S., Sanotskyy, Y., Smolanka, V., Yavorskaya, V., Bates, D., Evangelou, N., Hawkins, C., Mclean, B., O'Riordan, J., Price, S., Turner, B., Barnes, D., Zajicek, J., Honeycutt, W., Khan, O., Spikol, L., Stevens, J., Klinische Neurowetenschappen, and RS: MHeNs School for Mental Health and Neuroscience

Subjects
medicine.medical_specialty, biology, Nausea, business.industry, Incidence (epidemiology), Placebo-controlled study, General Medicine, Placebo, Gastroenterology, Surgery, chemistry.chemical_compound, Alanine transaminase, chemistry, Internal medicine, Relative risk, Teriflunomide, medicine, biology.protein, medicine.symptom, business, Leflunomide, medicine.drug
Abstract

Teriflunomide reduced the annualized relapse rate (0.54 for placebo vs. 0.37 for teri flunomide at either 7 or 14 mg), with relative risk reductions of 31.2% and 31.5%, respectively (P

Published
2011

12. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis

Author

Patti, F., Pozzilli, Carlo, Montanari, E., Pappalardo, A., Piazza, L., Levi, A., Onesti, Emanuela, Pesci, I., and Group On Quality Of Life In, Italian Study M. S.

Subjects
Employment, Male, medicine.medical_specialty, Multivariate analysis, Higher education, Health Status, Sexual Behavior, media_common.quotation_subject, Primary education, Disability Evaluation, Multiple Sclerosis, Relapsing-Remitting, Quality of life, medicine, Humans, Glatiramer acetate, education level, employment status, multiple sclerosis, qol, media_common, Expanded Disability Status Scale, business.industry, Patient Selection, Multiple sclerosis, medicine.disease, Italy, Neurology, Multivariate Analysis, Quality of Life, Physical therapy, Educational Status, Female, Aptitude, Neurology (clinical), business, medicine.drug
Abstract

Purpose To evaluate the effects of education level and employment status on health-related quality of life (HRQoL) in a large cohort of patients affected by relapsing-remitting multiple sclerosis (RRMS). Patients This study included 648 patients with RRMS attending 40 Italian MS centers. Inclusion criteria were an Expanded Disability Status Scale (EDSS) score between 1.0 and 5.5; stable disease on enrollment; and no previous treatment with interferons, glatiramer acetate, or immunosuppressive drugs. Quality of life (QoL) was evaluated by the Multiple Sclerosis Quality of Life-54 questionnaire (MSQoL-54). Results Employed patients scored significantly higher than other patient groups in the majority of MSQoL-54 domains. Similarly, patients with academic degrees and secondary education had higher scores than those with primary education (ie, eight years of education) in several domains of HRQoL. Patients who were employed with a high educational level achieved significantly better scores than unemployed patients with a lower educational level. In multivariate analysis, occupation and educational level were found to be significant and independent predictors of HRQoL. Conclusions The results of our study suggest the importance of sustaining employment after a recent diagnosis of MS. In addition, education has a great influence on HRQoL; a higher education level may determine a stronger awareness of the disease, and a better ability to cope with the challenges of a chronic disease such as MS. Multiple Sclerosis 2007; 13: 783-791. http://msj.sagepub.com

Published
2007

13. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

Author

Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G, Italian Mitoxantrone G.r.o.u.p. COLLABORATORS: Radaelli M, Esposito F, Moiola L, Colombo B, Rossi P, Marrosu MG, Frau J, Lorefice L, Coghe G, Savettieri G, Ragonese P, Cusimano V, Perini P, Rinaldi F, Vidali A, Bertolotto A, Malucchi S, Di Sapio A, Montanari E, Guareschi A, Rizzo A, Zaffaroni M, Baldini S, De Rossi N, Cordioli C, Rasia S, Salvetti M, Buttinelli C, Ausili Cefaro L, De Luca G, Tommaso D, Farina D, Fantozzi R, Ruggieri S, Hakiki B, Zipoli V, Portaccio E, Bartolozzi ML, Scandellari C, Stecchi S, Marchello LP, Palmeri B, Vitello G, Iaffaldano P, Lucchese G, Dattola V, Buccafusca M, Sola P, Simone AM, Barreca F, Patti F, Laisa P, Cavalla P, Masera S, Tavazzi E, Galgani S, Sacco R, Provinciali L, Maura D, LUS, Giacomo, Alfieri G, Ticca A, Piras ML, Maimone D, Bianca M, Iudice A, Giro ME, Galeotti M, Florio C, Spitalieri P, La Mantia L, Motti L, Rottoli MR, Granella F, Solaro C, Scarpini E, Servillo G, Cavalletti G., TEDESCHI, Gioacchino, Martinelli, V, Cocco, E, Capra, R, Salemi, G, Gallo, P, Capobianco, M, Pesci, I, Ghezzi, A, Pozzilli, C, Lugaresi, A, Bellantonio, P, Amato, Mp, Grimaldi, Lm, Trojano, M, Mancardi, Gl, Bergamaschi, R, Gasperini, C, Rodegher, M, Straffi, L, Ponzio, M, Comi, G, COLLABORATORS: Radaelli M, Italian Mitoxantrone G. r. o. u. p., Esposito, F, Moiola, L, Colombo, B, Rossi, P, Marrosu, Mg, Frau, J, Lorefice, L, Coghe, G, Savettieri, G, Ragonese, P, Cusimano, V, Perini, P, Rinaldi, F, Vidali, A, Bertolotto, A, Malucchi, S, Di Sapio, A, Montanari, E, Guareschi, A, Rizzo, A, Zaffaroni, M, Baldini, S, De Rossi, N, Cordioli, C, Rasia, S, Salvetti, M, Buttinelli, C, Ausili Cefaro, L, De Luca, G, Tommaso, D, Farina, D, Fantozzi, R, Ruggieri, S, Hakiki, B, Zipoli, V, Portaccio, E, Bartolozzi, Ml, Scandellari, C, Stecchi, S, Marchello, Lp, Palmeri, B, Vitello, G, Iaffaldano, P, Lucchese, G, Dattola, V, Buccafusca, M, Sola, P, Simone, Am, Barreca, F, Patti, F, Laisa, P, Cavalla, P, Masera, S, Tavazzi, E, Galgani, S, Tedeschi, Gioacchino, Sacco, R, Provinciali, L, Maura, D, Lus, Giacomo, Alfieri, G, Ticca, A, Piras, Ml, Maimone, D, Bianca, M, Iudice, A, Giro, Me, Galeotti, M, Florio, C, Spitalieri, P, La Mantia, L, Motti, L, Rottoli, Mr, Granella, F, Solaro, C, Scarpini, E, Servillo, G, and Cavalletti, G.

Published
2011

14. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

Author

Patti, F, Amato, Mp, Trojano, M, Bastianello, S, Tola, Mr, Goretti, B, Caniatti, L, DI MONTE, E, Ferrazza, P, BRESCIA MORRA, V, LO FERMO, S, Picconi, O, Luccichenti, G, Vecchio, R, Maimone, D, Messina, S, Gasperini, C, Orefice, V, Florio, C, Portaccio, E, Zipoli, V, Bertolotto, A, Bramant, P, Sessa, E, Centonze, D, Cottone, S, Salemi, G, Falcini, M, Gallo, P, Perini, P, Gigli, Gian Luigi, Giuliani, G, Grimald, Lm, Murri, L, Lugaresi, A, Monaco, F, Montanari, E, Motti, L, Neri, S, Paciello, M, Provinciali, L, Ragno, M, Rosati, G, Ruggieri, S, Tonali, P, Batocchi, Ap, DE CARO MF, Ghezzi, A, Zaffaroni, M, Zolo, P, Zorzon, M, Signorino, M, Scarpini, E, Durelli, L, Carolei, A, Todaro, M, Spitaleri, D, Tartaglione, A., Patti, F, Amato, Mp, Trojano, M, Bastianello, S, Tola, Mr, Goretti, B, Caniatti, L, Di Monte, E, Ferrazza, P, BRESCIA MORRA, Vincenzo, Lo Fermo, S, Picconi, O, Luccichenti, G, COGIMUS Study, Group, Vecchio, R, Maimone, D, Messina, S, Gasperini, C, Orefice, V, Brescia Morra, V, Florio, C, Amato, MP, Portaccio, E, Zipoli, V, Bertolotto, A, Bramanti, P, Sessa, E, Centonze, D, Cottone, S, Salemi, G, Falcini, M, Gallo, P, Perini, P, Gigli, GL, Giuliani, G, Grimaldi, LM, Murri, L, Lugaresi, A, Monaco, F, Montanari, E, Motti, L, Neri, S, Paciello, M, Provinciali, L, Ragno, M, Rosati, G, Ruggieri, S, Tola, MR, Tonali, P, Batocchi, AP, De Caro, MF, Ghezzi, A, Zaffaroni, M, Zolo, P, Zorzon, M, Signorino, M, Scarpini, E, Durelli, L, Carolei, A, Todaro, M, Spitaleri, D, Tartaglione, A, DI MONTE, E, BRESCIA MORRA, V, LO FERMO, S, and Zorzon, Marino

Subjects
Male, Pediatrics, Intelligence, Relapsing-Remitting, Neuropsychological Tests, Severity of Illness Index, Disability Evaluation, Cognition, Risk Factors, Odds Ratio, Prevalence, Neuropsychological assessment, Prospective Studies, Neurologic Examination, medicine.diagnostic_test, Cognitive impairmet. Cognitive function. Multiple Sclerosis. Neuropsychological assessment, Cognitive disorder, Neuropsychology, Age Factors, Middle Aged, Magnetic Resonance Imaging, Cognitive test, Treatment Outcome, Neurology, Italy, Female, Settore MED/26 - Neurologia, Psychology, Adult, medicine.medical_specialty, Multiple Sclerosis, Adolescent, Neurological examination, Risk Assessment, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Predictive Value of Tests, Immunologic Factors, Humans, Interferon-beta, Cognition Disorders, Cross-Sectional Studies, medicine, Expanded Disability Status Scale, Multiple sclerosis, McDonald criteria, medicine.disease, Physical therapy, Neurology (clinical)
Abstract

Background Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing–remitting (RR) MS is unclear. Objectives To study the prevalence of cognitive impairment and its relation with MRI disease measures in mildly disabled patients with RRMS. Methods Patients aged 18–50 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale (EDSS) score ≤4.0, who were enrolled in the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study, underwent baseline standardized MRI complete neurological examination and neuropsychological testing. Results A total of 550 patients were enrolled, 327 of whom underwent MRI assessments. Cognitive impairment (impaired performance in ≥3 cognitive tests) was present in approximately 20% of all patients and in the subgroup who underwent MRI. T2 hyperintense and T1 hypointense lesion volumes were significantly higher in patients with cognitive impairment (defined as impaired performance on at least three tests of the Rao’s battery) than those without. EDSS score was also significantly higher in cognitively impaired than in cognitively preserved patients. Disease duration, depression, and years in formal education did not differ significantly between cognitively impaired and cognitively preserved patients. T2 lesion volume, performance intelligence quotient, and age were significant predictors of cognitive impairment in this population. Weak correlations were found between performance on individual cognitive tests and specific MRI measures, with T1 and T2 lesion volumes correlating with performance on most cognitive tests. Conclusions Cognitive impairment occurs in approximately one-fifth of mildly disabled patients with MS and is associated with specific MRI disease measures. Assessment of cognitive function at diagnosis could facilitate the identification of patients who may benefit from therapeutic intervention with disease-modifying therapies to prevent further lesion development.

Published
2009

16. Variational Approach to the Electromagnetic Field Computation in Dielectric Dispersive Media

Author

I. Montanari, E. Dileo, M. Fabbri and Massimo Fabbri

Subjects
Radiation, Differential equation, Computation, Mathematical analysis, Dielectric, Finite element method, Electronic, Optical and Magnetic Materials, Classical mechanics, Variational method, Dissipative system, Boundary value problem, Electrical and Electronic Engineering, Mathematics, Vector potential
Abstract

A variational model and the related differential model for the field computation in dielectric dispersive media are presented. An electromagnetic problem has unique solution when initial, final, and boundary conditions are known. These conditions are completely defined by using the variational formulation of the problem because of the intrinsic properties of this approach. In fact, the search for stationaty states of the Lagrange integral leads naturally to obtaining both the differential equations describing the system and all the conditions for their unique solution. The adopted formalism allows us to carry on calculations for electromagnetic dissipative systems and introduces "mirror-image" system described by a fictitious vector potential. Moreover, the variational formulation can be directly applied in the finite element method.

Published
2001

18. Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging

Author

Yeung, Tp, Wang, Y, He, W, Urbini, B, Gafà, R, Ulazzi, L, Yartsev, S, Bauman, G, Lee TY, Fainardi, E, Project of Emilia-Romagna Region on Neuro-Oncology (PERNO) Study Group Participants :Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., (Bologna), Trocino C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., (Forlı`-Cesena), Strumia S., Faedi, M., (IRCCS Istituto Scientifico Romagnolo per lo Studio, e la Cura dei Tumori), Casmiro, M., Gamboni, A., Rasi, F. (Faenza R. A. )., (Lugo, Cruciani G., RA), Cenni, P., Dazzi, C., Guidi, A. R., (Ravenna), Zumaglini F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., (Rimini), Viti B., (Cattolica, Sintini M., RN), Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., (Modena), Zunarelli E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C. (Carpi M. O. )., Iaccarino, C, Ragazzi, M., Rizzi, R., (Istituto di Ricovero e Cura a Carattere Scientifico, Zuccoli G., Reggio, Emilia), Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Urbini, B., (Ferrara), Zini G., Giorgi, C., Montanari, E. (Fidenza P. R. )., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, Em., (Parma), Torelli P., Immovilli, P., Morelli, N., (Piacenza), Vanzo C., and Nobile, C. (Padova).

Subjects
Cancer Research, medicine.medical_specialty, Neuroradiology unit, Neurology, Oncology, business.industry, General surgery, Medicine, Neurology (clinical), business
Abstract

Baruzzi A. (Chair), Albani F., Calbucci F., D’Alessandro R., Michelucci R. (IRCCS Institute of Neurological Sciences, Bologna, Italy), Brandes A. (Department of Medical Oncology, Bellaria-Maggiore Hospitals, Bologna, Italy), Eusebi V. (Department of Hematology and Oncological Sciences ‘‘L. & A. Seragnoli’’, Section of Anatomic Pathology at Bellaria Hospital, Bologna, Italy), Ceruti S., Fainardi E., Tamarozzi R. (Neuroradiology Unit, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy), Emiliani E. (Istituto Oncologico Romagnolo, Department of Medical Oncology, Santa Maria delle Croci Hospital, Ravenna, Italy), Cavallo M. (Division of Neurosurgery, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy).

Published
2015

19. IPN localizations of Konus short gamma-ray bursts

Author

Pal'shin, V. D., Hurley, K., Svinkin, D. S., Aptekar, R. L., Golenetskii, S. V., Frederiks, D. D., Mazets, E. P., Oleynik, P. P., Ulanov, M. V., Cline, T., Mitrofanov, I. G., Golovin, D. V., Kozyrev, A. S., Litvak, M. L., Sanin, A. B., Boynton, W., Fellows, C., Harshman, K., Trombka, J., McClanahan, T., Starr, R., Goldsten, J., Gold, R., Rau, A., von Kienlin, A., Savchenko, V., Smith, D. M., Hajdas, W., Barthelmy, S. D., Cummings, J., Gehrels, N., Krimm, H., Palmer, D., Yamaoka, K., Ohno, M., Fukazawa, Y., Hanabata, Y., Takahashi, T., Tashiro, M., Terada, Y., Murakami, T., Makishima, K., Briggs, M. S., Kippen, R. M., Kouveliotou, C., Meegan, C., Fishman, G., Connaughton, V., Boer, M., Guidorzi, C., Frontera, F., Montanari, E., Rossi, F., Feroci, M., Amati, L., Nicastro, L., Orlandini, M., Del Monte, E., Costa, E., Donnarumma, I., Evangelista, Y., Lapshov, I., Lazzarotto, F., Pacciani, L., Rapisarda, M., Soffitta, P., Di Cocco, G., Fuschino, F., Galli, M., Labanti, C., Marisaldi, M., Atteia, J. -L., Vanderspek, R., and Ricker, G.

Subjects
High Energy Astrophysical Phenomena (astro-ph.HE), Astrophysics::High Energy Astrophysical Phenomena, Physics::Space Physics, FOS: Physical sciences, Astrophysics - High Energy Astrophysical Phenomena
Abstract

Between the launch of the \textit{GGS Wind} spacecraft in 1994 November and the end of 2010, the Konus-\textit{Wind} experiment detected 296 short-duration gamma-ray bursts (including 23 bursts which can be classified as short bursts with extended emission). During this period, the IPN consisted of up to eleven spacecraft, and using triangulation, the localizations of 271 bursts were obtained. We present the most comprehensive IPN localization data on these events. The short burst detection rate, $\sim$18 per year, exceeds that of many individual experiments., Comment: Published version

Published
2013
Full Text
View/download PDF

20. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

Author

Wolinsky, Js, Narayana, Pa, Nelson, F, Datta, S, O'Connor, P, Confavreux, C, Comi, G, Kappos, L, Olsson, Tp, Truffinet, P, Wang, L, Miller, A, Freedman MSMaida, E, Auff, E, Fazekas, F, Berger, T, Bhan, V, Bouchard, Jp, Duquette, P, Freedman, M, Grand'Maison, F, Kremenchutzky, M, Bourque, C, Marrie, Ra, Melanson, M, Patry, D, Oger, J, Stefanelli, M, Jacques, F, Venegas, P, Miranda, M, Barrientos, N, Tenhamm, E, Gloger, S, Rohde, G, Mares, J, Frederiksen, J, Stenager, E, Haldre, S, Gross Paju, K, Elovaara, I, Sumelahti, Ml, Erälinna, Jp, Färkkilä, M, Harno, H, Reunanen, M, Jolma, T, Camu, W, Clavelou, P, Magy, L, Debouverie, M, Edan, G, Lebrun Frenay, C, Moreau, T, Pelletier, J, Roullet, E, Alamowitch, S, Clanet, M, Hautecoeur, P, Damier, P, Rumbach, L, Chan, A, Schimrigk, S, Haas, J, Lensch, E, Diener, H, Limmroth, V, Anders, D, Berghoff, M, Oschmann, P, Stangel, M, Frese, A, Kiefer, R, Marziniak, M, Zettl, U, Stark, E, Jendroska, K, Reifschneider, G, Amato, Mp, Cosi, V, Gallo, Paolo, Gasperini, C, Ghezzi, A, Trojano, M, Pozzilli, C, Montanari, E, Zwanikken, Cp, Jongen, Pj, Centrum, Ms, Van Munster ET, Hupperts, Rm, Anten, B, Sanders, Ea, Celius, E, Hovdal, H, Krogseth, Sb, Kozubski, W, Kwiecinski, H, Czlonkowska, A, Stelmasiak, Z, Selmaj, K, Hasiec, T, Fryze, W, Drozdowski, W, Kochanowicz, J, Cunha, L, De Sá, J, Harrington Sena, A, Odinak, M, Skoromets, A, Gusev, E, Boiko, A, Lashch, N, Stolyarov, I, Belova, A, Malkova, N, Doronin, B, Yakupov, E, Brundin, L, Hillert, J, Karabudak, R, Irkec, C, Idiman, E, Turan, O, Efendi, H, Gedizlioglu, M, Buchakchyyska, N, Goloborodko, A, Ipatov, A, Kobets, S, Lebedynets, V, Moskovko, S, Yushchenko, Oi, Sanotskyy, Y, Smolanka, V, Yavorskaya, V, Bates, D, Evangelou, N, Hawkins, C, Mclean, B, O'Riordan, J, Price, S, Turner, B, Barnes, D, Zajicek, J, Honeycutt, W, Khan, O, Spikol, L, and Stevens, J.

Published
2013

21. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

Author

Khatri, B, Barkhof, F, Comi, G, Hartung, Hp, Kappos, L, Montalban, X, Pelletier, J, Stites, T, Wu, S, Holdbrook, F, Zhang auberson, L, Francis, G, Cohen, Ja, Cohen, J, Easton, Jd, Calandra, T, Dimarco, J, Hudson, L, Kesselring, J, Laupacis, A, Temkin, N, Weinshenker, B, Zarbin, M, Poppe, P, Luetic, G, Cristiano, E, Caceres, F, Garcea, O, Correale, J, Ballario, C, Piedrabuena, R, Pollard, J, Beran, R, Hodgkinson, S, Schwartz, R, Heard, R, King, J, Butzkueven, H, Maida, Em, Vass, K, Franta elmer, C, Berger, T, Aichner, F, Ladurner, G, Bissay, V, Sindic, C, D'Hooghe, M, Mulleners, E, Damasceno, B, Barreira, A, Naylor, R, Alvarenga, R, Bacellar, A, Haussen, S, Duquette, P, Antel, J, Lamontagne, A, Grand'Maison, F, Freedman, M, Christie, S, O'Connor, P, Vorobeychik, G, Devonshire, V, Ramadan, M, Hamdy, S, Reda, E, Hashem, S, Fouad, M, Lebrun frenay, C, Clanet, M, Brochet, B, Debouverie, M, Heinzlef, O, Ziemssen, T, Koehler, W, Tiel wilck, K, Bachus, R, Altmann, N, Faiss, J, Baum, K, Dressel, A, Luckner, K, Ebke, M, Stangel, M, Diener, Hc, Bethke, F, Limmroth, V, Maschke, M, Thoemke, F, Reifschneider, G, Diehm, R, Wildemann, B, Melms, A, Rauer, S, Karlbauer, G, Berthele, A, Lang, M, Tumani, H, Krauseneck, P, Klein, M, Papadimitriou, A, Karageorgiou, K, Liakopoulos, D, Tascos, N, Plaitakis, A, Papathanasopoulos, P, Panczel, G, Jakab, G, Csiba, L, Komoly, S, Csanyi, A, Bartos, L, Centonze, D, Pozzilli, C, Marrosu, Mg, Bertolotto, A, Mancardi, GIOVANNI LUIGI, Scarpini, E, Protti, A, Ghezzi, A, Capra, R, Bergamaschi, R, Gallo, P, Stecchi, S, Montanari, E, Tola, Mr, Amato, Mp, Silvestrini, M, Lugaresi, A, Trojano, M, Morra, Vb, Ruggieri, S, Patti, F, Kim, Sm, Lee, Kh, Kim, Hj, Park, Sp, Ginestal, R, Salgado, Av, Fontoura, P, Cunha, L, Sousa, L, Mj, Sá, Pedrosa, R, Arbizu, T, Arroyo, R, Merino, Ja, Fernandez, O, Izquierdo, G, Casanova, B, Antigüedad, A, Goebels, N, Young, C, Lee, M, Chaudhuri, A, Nicholas, R, Martinez, Ac, Preiningerova, J, Greco, D, Gross, J, Newman, S, Mitchell, G, Pawar, G, Freedman, Sm, Kaufman, M, Absher, J, Kantor, D, Ayala, R, Honeycutt, W, Shafer, S, Steingo, B, Delgado, S, Cascione, M, Brock, C, Keegan, A, Laganke, C, Hunter, S, Wilson, E, Mazhari, A, Bauer, W, Singer, B, Lynch, S, Rowe, V, Hutton, G, Gazda, S, Dihenia, B, Campagnolo, D, Chippendale, T, Ash, P, Jung, L, Olek, M., Radiology and nuclear medicine, NCA - Multiple Sclerosis and Other Neuroinflammatory Diseases, Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group, Lugaresi A, Diener, Hans Christoph (Beitragende*r), Khatri, B, Barkhof, F, Comi, G, Hartung, Hp, Kappos, L, Montalban, X, Pelletier, J, Stites, T, Wu, S, Holdbrook, F, Zhang Auberson, L, Francis, G, Cohen, Ja, BRESCIA MORRA, Vincenzo, Comi, Giancarlo, TRANSFORMS Study, Group, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, and UCL - (SLuc) Service de neurologie

Subjects
Adult, Male, medicine.medical_specialty, multiple sclerosis, interferon beta, fingolimod, treatment, Multiple Sclerosis, Adolescent, Medizin, Phases of clinical research, Relapsing-Remitting, Injections, Intramuscular, Young Adult, Humans, Adjuvants, Immunologic, Interferon-beta, Immunosuppressive Agents, Multiple Sclerosis, Relapsing-Remitting, Treatment Outcome, Middle Aged, Propylene Glycols, Sphingosine, Female, law.invention, Injections, Randomized controlled trial, law, Immunologic, analogs /&/ derivatives/therapeutic use, Internal medicine, Fingolimod Hydrochloride, Medicine, Adjuvants, Young adult, Intramuscular, business.industry, Multiple sclerosis, Interferon beta-1a, medicine.disease, Fingolimod, Surgery, drug therapy/pathology/physiopathology, Clinical research, therapeutic use, Adolescent, Adult, Female, Humans, Immunosuppressive Agents, therapeutic use, Injections, Intramuscular, Interferon-beta, therapeutic use, Male, Middle Aged, Multiple Sclerosis, drug therapy/pathology/physiopathology, Propylene Glycols, therapeutic use, Sphingosine, analogs /&/ derivatives/therapeutic use, Treatment Outcome, Young Adult, therapeutic use, Settore MED/26 - Neurologia, Neurology (clinical), business, medicine.drug
Abstract

In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a. We had two aims in our extension: to compare year 2 with year 1 in the switched patients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24 months the treatment groups as originally randomised to assess the effect of delaying the start of treatment with fingolimod. METHODS: Patients randomly assigned to receive 0.5 mg or 1.25 mg daily oral fingolimod in the core study continued with the same treatment in our extension; patients who originally received 30 μg weekly intramuscular interferon beta-1a were randomly reassigned (1:1) to receive either 0.5 mg or 1.25 mg fingolimod. The initial randomisation and dose of fingolimod assigned for the extension remained masked to the patients and investigators. As in the core study, re-randomisation was done centrally in blocks of six and stratified according to site. Our efficacy endpoints were annualised relapse rate (ARR), disability progression, and MRI outcomes. Our within-group analyses were based on the intention-to-treat and safety populations that entered our extension study. Our between-group analyses were based on the intention-to-treat and safety populations from the core study. This study is registered with ClinicalTrials.gov, number NCT00340834. FINDINGS: 1027 patients entered our extension and received the study drug, and 882 completed 24 months of treatment. Patients receiving continuous fingolimod showed persistent benefits in ARR (0.5 mg fingolimod [n=356], 0.12 [95% CI 0.08-0.17] in months 0-12 vs 0.11 [0.08-0.16] in months 13-24; 1.25 mg fingolimod [n=330], 0.15 [0.10-0.21] vs 0.11 [0.08-0.16]; however, in patients who initially received interferon beta-1a, ARR was lower after switching to fingolimod compared with the previous 12 months (interferon beta-1a to 0.5 mg fingolimod [n=167], 0.31 [95% CI 0.22-0.43] in months 0-12 vs 0.22 [0.15-0.31], in months 13-24 p=0.049; interferon beta-1a to 1.25 mg fingolimod [n=174], 0.29 [0.20-0.40] vs 0.18 [0.12-0.27], p=0.024). After switching to fingolimod, numbers of new or newly enlarging T2 and gadolinium (Gd)-enhancing T1 lesions were significantly reduced compared with the previous 12 months of interferon beta-1a therapy (p

Published
2011

22. Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis

Author

Solari, A, Mattarozzi, K, Vignatelli, L, Giordano, A, Russo, P, Messmeruccelli, M, D'Alessandro, R, Pucci, E, Martinelli, V, Uccelli, Mm, Borreani, C, Trojano, M, Heesen, C, Mancardi, Gl, Milanese, C, Galimberti, S, Calabrese, D, Ferrari, G, Confalonieri, P, Mantegazza, R, Maggi, L, Colombo, B, Esposito, F, Moiola, L, Rodegher, M, Radaelli, M, Granella, F, Immovilli, P, Dalla Bella, E, Lugaresi, A, De Luca, G, Mattoscio, M, Di Ioia, M, Travaglini, D, Farina, D, Zimatore, G, Plasmati, I, Tortorella, C, Orsolamalpighi, S, Guidolin, L, Leone, M, Motti, L, Tola, Mr, Montanari, E, Guareschi, A, Pesci, I, Pattini, M, Feo, C, Torricelli, L, Santangelo, M, Stecchi, S, Scandellari, C, Balugani, R, La Mola, L, Montagna, P, Pizza, F, Avoni, P, Baldin, E, Delaj, L, Rinaldi, R, Baldi, E, Caniatti, L, Milani, P, Mussuto, V, Manzoni, M, Casmiro, M, Fiorani, L, Galeotti, M, Guerrini, C, Neri, W, Mambelli, L, Malagù, S, Naldi, P, Calzoni, S, Collimedaglia, L, Pietrolongo, E, Di Tommaso, V, Pace, M, Benedetti, M, Rossi, F, Pastoretrossello, M, Faccioli, L, Spinardi, L., Solari A., Mattarozzi K., Vignatelli L., Giordano A., Russo P.M., Uccelli M.M., D'Alessandro R., Montagna P., Pizza F., Avoni P., Baldin E., Delaj L., SIMS-Trial group, and GERONIMUS group.

Subjects
Questionnaires, Adult, Male, medicine.medical_specialty, Neurology, Multiple Sclerosis, Psychometrics, Adolescent, Adolescent, Adult, Aged, Cognition, physiology, Communication, Disease Progression, Early Diagnosis, Factor Analysis, Statistical, Female, Humans, Male, Middle Aged, Multiple Sclerosis, psychology, Patient Satisfaction, Physician-Patient Relations, Psychiatric Status Rating Scales, Questionnaires, Reproducibility of Results, Young Adult, Newly diagnosed, psychology, Young Adult, Patient satisfaction, DIAGNOSIS COMMUNICATION, Cognition, Surveys and Questionnaires, medicine, Humans, Aged, Psychiatric Status Rating Scales, Physician-Patient Relations, PSYCHOMETRICS, business.industry, Multiple sclerosis, Communication, Reproducibility of Results, Statistical, Middle Aged, medicine.disease, Surgery, Clinical trial, Early Diagnosis, Patient Satisfaction, physiology, PATIENT-REPORTED OUTCOMES, Physical therapy, Disease Progression, Female, Neurology (clinical), business, Factor Analysis, Statistical, Factor Analysis
Abstract

Background: We describe the development and clinical validation of a patient self-administered tool assessing the quality of multiple sclerosis diagnosis disclosure. Method: A multiple sclerosis expert panel generated questionnaire items from the Doctor’s Interpersonal Skills Questionnaire, literature review, and interviews with neurology inpatients. The resulting 19-item Comunicazione medico-paziente nella Sclerosi Multipla (COSM) was pilot tested/debriefed on seven patients with multiple sclerosis and administered to 80 patients newly diagnosed with multiple sclerosis. The resulting revised 20-item version (COSM-R) was debriefed on five patients with multiple sclerosis, field tested/debriefed on multiple sclerosis patients, and field tested on 105 patients newly diagnosed with multiple sclerosis participating in a clinical trial on an information aid. The hypothesized monofactorial structure of COSM-R section 2 was tested on the latter two groups. Results: The questionnaire was well accepted. Scaling assumptions were satisfactory in terms of score distributions, item—total correlations and internal consistency. Factor analysis confirmed section 2’s monofactorial structure, which was also test—retest reliable (intraclass correlation coefficient [ICC] 0.73; 95% CI 0.54—0.85). Section 1 had only fair test—retest reliability (ICC 0.45; 95% CI 0.12—0.69), and three items had 8—21% missed responses. Conclusions: COSM-R is a brief, easy-to-interpret MS-specific questionnaire for use as a health care indicator.

Published
2010

26. Charge order and tilt modulation in multiferroic (KxMxM1-xF3)-M-II-F-III (0.4 < x < 0.6) transition metal fluorides with tetragonal tungsten bronze structure

Author

Fabbrici S, Montanari E, Righi L, Calestani G, and Migliori A

Abstract

Transition metal fluorides with tetragonal tungsten bronze (TTB) structure, having general formula (KxMxM1-xF3)-M-II-F-III with 0.4 < x < 0.6 and M belonging to transition metals, have been studied over the past decades because of the frustrated magnetic ordering arising at low temperature. We investigated the structural properties of TTB fluorides by transmission electron microscopy (TEM). The results, coupled with an accurate structure analysis performed by single-crystal XRD on K0.53FeF3, revealed ferroelectricity and a unified structural description of these materials, where charge order and tilt modulations coexist, each one with its own periodicity differently commensurate to the conventional TTB cell. Whereas the charge order is peculiar of the mixed valence fluorides,the nature of the tilt modulation is clearly associable to the structural features of TTB niobates, suggesting also for the fluoride bronzes the existence of a generalized ferroelectric-ferroelastic behavior at room temperature.

Published
2004
Full Text
View/download PDF

28. Long and faint GRBs in archival BeppoSAX-WFC data

Author

Frontera, F., Montanari, E., Guidorzi, C., Kippen, R., Woods, P., Zand, J., and Heise, J.

Subjects
Astrophysics (astro-ph), FOS: Physical sciences, Astrophysics
Abstract

In an ongoing effort to search for X-ray transients on diverse time scales in the data archive of the BeppoSAX Wide Field Cameras we have identified four GRBs that are long (between 540 and at least 2550 s) and faint (with 3 events having peak fluxes below 7X10^-9 erg/s/cm2 in 2-10 keV). Three of the events were covered and detected by BATSE, suggesting that there may be a substantial number of bursts still hidden in the BATSE database. A spectral analysis of the three events shows that, although soft, they are not typical X-ray flashes. The fourth event (not covered by BATSE) is within 3' coincident with a double-lobed radio galaxy. The chance probability is estimated at 0.001. If real, the association would be remarkable., Comment: 5 pages, 4 figures (last one in color), to be published in Proc. "GRBs in the afterglow era: 3rd Rome workshop (2002)", eds. L. Piro, F. Frontera, N. Masetti, M Feroci

Published
2003
Full Text
View/download PDF

33. Prompt and afterglow emission from the x-ray-rich GRB 981226 observed with bepposax

Author

Frontera, F., Antonelli, L. A., Amati, L., Montanari, E., Enrico Costa, Dal Fiume, D., Giommi, P., Feroci, M., Gennaro, G., Heise, J., Masetti, N., Muller, J. M., Nicastro, L., Orlandini, M., Palazzi, E., Pian, E., Piro, L., Soffitta, P., Stornelli, M., In T Zand, J. J. M., Frail, D. A., Kulkarni, S. R., and Vietri, M.

39. The GRB of 1999 January 23: Prompt emission and broad-band afterglow modeling

Author

Corsi, A., Piro, L., Kuulkers, E., Lorenzo Amati, Antonelli, L. A., Costa, E., Feroci, M., Frontera, F., Guidorzi, C., Heise, J., In T Zand, J., Maiorano, E., Montanari, E., Nicastro, L., Pian, E., and Soffitta, P.

Subjects
Astrophysics::High Energy Astrophysical Phenomena, Astrophysics (astro-ph), FOS: Physical sciences, Astrophysics
Abstract

We report on BeppoSAX simultaneous X- and gamma-ray observations of the bright gamma-ray burst (GRB) 990123. We present the broad-band spectrum of the prompt emission, including optical, X- and gamma-rays, confirming the suggestion that the emission mechanisms at low and high frequencies must have different physical origins. We discuss the X-ray afterglow observed by the Narrow Field Instruments (NFIs) on board BeppoSAX and its hard X-ray emission up to 60 keV several hours after the burst, in the framework of the standard fireball model. The effects of including an important contribution of Inverse Compton scattering or modifying the hydrodynamics are studied., 4 pages, 3 figures, minor changes; accepted for publication in Il Nuovo Cimento, proceedings of the 4th Workshop on Gamma-Ray Bursts in the Afterglow Era, Rome,18-22 October 2004. For more details, see astro-ph/0504607 (accepted in A&A)

41. Guillain-Barre syndrome variants in Emilia-Romagna, Italy, 1992-3: Incidence, clinical features, and prognosis

Author

Casmiro, M., Guarino, M., D Alessandro, R., Pasquinelli, M., Curro Dossi, B., Neri, W., Guidi, C., Gessaroli, M., Rasi, F., Fabbri, R., Mazzini, G., Rebucci, G. G., Padoan, G., Callegarini, C., Ciucci, G., Guidi, A. R., Galeotti, M., Bianchedi, G., Tola, M. R., Govoni, V., Enrico Granieri, Tralli, G., Tugnoli, V., Mussuto, V., Azzimondi, G., Baldrati, A., Laudadio, S., Sacquegna, T., Salvi, F., Ambrosetto, G., Sorgato, P., Ferrari, V., Gentilini, M., Colombo, A., Merelli, E., Miele, V., Lolli, V., Santangelo, M., Motti, L., Guidetti, D., Solime, F., Granella, F., Pavesi, G., Allegri, I., Falco, L., Scaglioni, A., Montanari, E., Cammarata, S., Poli, V., and Lugaresi, A.

46. Liver and thyroid function and autoimmunity during interferon-β1b treatment for MS

Author

Durelli, L., Ferrero, B., Oggero, A., Verdun, E., Ghezzi, A., Montanari, E., Zaffaroni, M., Trojano, M., Giuliani, F., Salvi, F., Stecchi, S., Reggio, A., Reggio, E., Negri, G., Ludovico, L., Mancardi, G. L., Inglese, M., Carolei, A., Totaro, R., Milanese, C., La Mantia, L., Caputo, D., Mini, M., Mendozzi, L., Cotrufo, R., Lus, G., Cosi, V., Romani, A., Gallai, V., Sarchielli, P., Ugo Nocentini, Rizzato, B., Tonali, P. A., Massaro, A. R., Rosati, G., Sotgiu, S., Annunziata, P., Barbero, P., Isoardo, G. L., Pipieri, A., Ricci, A., Cucci, M. A., Clerico, M., Bergamaso, B., Aimo, G., Giorda, L., Bortolon, F., Stenta, G., Sormani, M. P., Beckmann, K., Ecari, U., and Ciampini, M.

47. Exposure assessment for a population-based case-control study combining a job-exposure matrix with interview data

Author

Semple, Sean E., Finlay Dick, John Cherrie, Seaton, A., Dick, F., Haites, N., Osborne, A., Grant, F., Semple, S., Joshi, S., Adiakpan, N., Sutherland, S., Prescott, G., Scott, N., Counsell, C., Coleman, R., Primrose, W., Srivastava, P., Mutti, A., Buzio, L., Calzetti, S., Palma, G., Montanari, E., Mozzoni, P., Negrotti, A., Scaglioni, A., Scotti, E., Söderkvist, P., Ahmadi, A., Axelson, O., Fall, P. A., Georgsson, E., Hällsten, A. L., Molbaek, A., Segrell, N. D., Å, Schippert, Tondel, M., Otelea, M., Luparu, R., and Tinischi, M.

Subjects
Gerontology, medicine.medical_specialty, Time Factors, exposure assessment, Job-exposure matrix, Population, job-specific questionnaires, expert systems, Population based, Parkinson' s disease, occupational, Risk Assessment, Interview data, Occupational medicine, Environmental health, Occupational Exposure, Surveys and Questionnaires, medicine, Humans, Occupations, Parkinson Disease, Secondary, education, Exposure assessment, Sweden, education.field_of_study, business.industry, Romania, Public Health, Environmental and Occupational Health, Case-control study, Italy, Scotland, Case-Control Studies, Solvents, Occupational exposure, business
Abstract

A system that combines the ease of use of a job-exposure matrix while taking into account job-specific data is needed. This study aimed to produce a detailed method for combining interview data with expert assessments for a large population-based case-control study of Parkinson's disease.An interview-administered core questionnaire with a series of questions that triggers substance-specific questionnaires to gather information on key parameters is administered. Using a job-exposure matrix to generate base estimates, assessors can modify this estimate of exposure intensity using worker-specific data such as the use of control measures, reports of substance-specific acute symptoms, and the quantity of material being processed. Detailed guidance for making adjustments to exposure estimates for these modifiers is presented.The method has been partially validated through the use of a comparison of estimates for a separate cohort with previously validated exposure reconstructions. Agreement was high, with a Spearman's rho of 0.89 (P0.01). The results from a quality assurance system employed as part of the methodology show a high degree of repeatability in generated exposure values both over time (Spearman's rho 0.98, P0.01) and between different assessors (Spearman's rho 0.88, P0.01).The method provides detailed quantitative exposure indices for occupational epidemiology. It has particular strengths both in terms of ease and speed of use. It is hoped that it will provide a useful structure for future epidemiologic work.

49. The costs of multiple sclerosis: A cross-sectional, multicenter cost-of-illness study in Italy

Author

Amato, M. P., Battaglia, M. A., Caputo, D., Fattore, G., Gerzeli, S., Pitaro, M., Reggio, A., Trojano, M., Piazza, G., Valiani, R., Coniglio, M. G., Paciello, M., Ciccarelli, M., Branca, F., Olivieri, R. L., Sibilia, G., Orefice, G., Campese, O., Mandarini, A., Montanari, E., Ludovico, L., Motti, L., Sabadini, R., Stecchi, S., Scandellari, C., Tola, M. R., Gragnaniello, D., Cargnelutti, D., Bergonzi, P., Falcone, M., Gigli, L., Zadini, A., Pelizon, C., Galgani, S., Fele, M. R., Massaro, A. R., Pascalis, D., Nocentini, U., Pozzilli, C., Mancini, A., Spadaro, M., Fantozzi, R., Solaro, C., giovanni luigi mancardi, Tartaglione, A., Parodi, S., Capra, R., Galluzzi, S., Cosi, V., Bergamaschi, R., Martinelli, V., Gironi, M., Scarlato, G., Scarpini, E., Zibetti, A., Baldini, S. M., Lugaresi, A., Iarlori, C., Marzoli, F., Carolei, A., Totaro, R., Viti, B., Taus, C., Melato, M., Gasco, P., Colla, L., Morgando, D., Di Sapio, A., Perla, F., Rosso, M. G., Giuliani, F., Paolicelli, D., Simone, P., Cioffi, R., Patti, F., Savettieri, G., Salemi, G., Conte, S., Annunziata, P., Pieri, S., Bardi, C., Marcacci, G., Meucci, G., Lombardo, F., Lovaste, M. G., Orrico, D., Sarchielli, P., Urciuoli, R., Giuglietti, M., Tavolato, B., Marangoni, S., Bortolon, F., and Toso, V.

Catalog

Books, media, physical & digital resources
See catalog results